Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.
about
Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpuraPathogenesis of thrombotic microangiopathiesClinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in KoreaCritical appraisal of eculizumab for atypical hemolytic uremic syndromeThe role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpuraADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpuraTransplant-associated thrombotic microangiopathy: opening Pandora's box.Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012.Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura.Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood.Management of thrombotic thrombocytopenic purpura.Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome.Staphylococcus aureus bacteremia as a cause of early relapse of thrombotic thrombocytopenic purpura.Design of the prospective randomized study for the treatment of patients with thrombotic microangiopathy. PRODROMI Study Group.Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes.BMT: Bone Marrow Transplant Associated Thrombotic Microangiopathy.Cryoprecipitate-reduced plasma:rationale for use and efficacy in the treatment of thrombotic thrombocytopenic purpura.Patients with thrombotic thrombocytopenic purpura commonly develop metabolic alkalosis during therapeutic plasma exchange.Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura.Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy.Management of a patient with HIV infection-induced anemia and thrombocytopenia who presented with thrombotic thrombocytopenic purpura.HIV associated thrombotic microangiopathy.Infectious diseases as a trigger in thrombotic microangiopathies in intensive care unit (ICU) patients?Multiorgan thrombotic disorders in systemic lupus erythematosus: a common link?Atypical haemolytic uraemic syndrome as a complication of induction chemotherapy for acute lymphoblastic leukaemia.Autoimmune thrombocytopenias.Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.Disseminated histoplasmosis presenting as thrombotic microangiopathy.Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.Thrombotic thrombocytopenic purpura after percutaneous coronary intervention.Thrombotic thrombocytopenic purpura: survival by "giving a dam"Bench-to-bedside review: thrombocytopenia-associated multiple organ failure--a newly appreciated syndrome in the critically illTargeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura.Thrombotic microangiopathies: an update.Clinical surveillance of thrombotic microangiopathies in Scotland, 2003-2005.The role of von Willebrand factor in hemorrhagic and thrombotic disorders.Treatment of thrombotic microangiopathies with plasma exchange.Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.Treating TTP/HUS with plasma exchange: a single centre's 25-year experience.
P2860
Q24620546-BFF03205-2126-4544-B522-719C2FE1889BQ24658043-2A78436D-C487-495B-96ED-1239F7B2B14CQ26739894-FB2A482B-F601-4C68-AC4D-1A772DF38CA3Q26750692-53D9344F-8512-4C3A-8A80-B7E1E20B269DQ28080631-EC6AD61E-0975-48A7-B3BE-82106FA98F30Q28083264-A47A606D-D1D2-4FF5-A08B-4CC946871885Q30235311-C9099F14-F7F9-46D1-A222-E2EE8F35C0A9Q30276550-81B0AAFC-F6DE-4DCD-AEC4-0A52BFBC2B5AQ31077457-3B0C9763-44A1-4F89-A3B7-850B9B299A98Q33328894-F824A2B4-A6F5-4B37-99E2-9C3CE6C56DC5Q33330536-6632ACCA-CFC3-4965-ADB9-8F9307FB8FE0Q33333063-D1949832-EA9D-4E63-8DE4-FA9FD2B73C26Q33333765-4E01E146-17B7-4852-8306-3E319FFFEAF9Q33334110-C8FB0C55-E86F-48F7-AB51-55779870E224Q33335399-C5AE87C4-97A1-4DCE-B9C9-C74D5836C3ABQ33337015-F83B068F-D4ED-47CE-80FC-34672EC57BDCQ33337686-3BA9B587-D3F7-454F-8D24-679923C678E4Q33337694-4F383BB5-5372-4D03-A2B1-E27A8F283599Q33340211-4742F6BD-A394-4167-ACA2-53B711184107Q33340216-AD006AEC-4D7C-4BBC-B24E-425B4ED2F438Q33340971-A8CADADF-6F77-4DD4-B5D9-0BCC2790C5AEQ33341452-CFD6C63B-B3A5-4D05-8879-CBFD45C14497Q33344468-9E96D799-B9C4-4C95-A307-4F8D3C77232FQ33346625-06F1F221-C91F-4C1A-9D02-D25F661EB270Q33350163-9B3D9B95-6DB1-473B-9B04-B31EE34C0E02Q33360999-43F22C1C-C64B-49DE-B9F0-4F04D8E7A5D0Q33363539-F7FDA57F-ABA4-44BF-A48F-08F3AD11649AQ33369765-D010E7E1-8894-4978-A96B-06CB066BD826Q33371916-EF6419E0-3953-43C9-90E8-D0A6B71C29DDQ33372115-C3FE9615-E3E4-4681-8245-18E382FF5A9BQ33372278-A42D273B-E5A9-4974-A824-65467F666E0AQ33373067-99128D1E-A6D9-4272-899A-03E0C849E3D2Q33373238-2431CB6F-208E-475A-9E78-B170F59ABB57Q33374294-A42441D6-F519-4476-B255-C3C3D4AA9B3BQ33374370-19F04388-85B2-41F7-B00F-189C6C0DCC68Q33374424-C773F9E4-7586-40FB-B86E-618371E73A63Q33374578-8317255F-5214-4E22-A74A-17412E9C6FD1Q33374580-5C7A2C84-5615-4811-93C3-4F2CA978D8B2Q33377727-A8D914E4-48F2-49FF-B6DA-00AEAF38CF35Q33380686-4193A218-EB38-42B1-B1D0-153A5AA43E67
P2860
Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.
description
1991 nî lūn-bûn
@nan
1991 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Improved survival in thromboti ...... al experience in 108 patients.
@ast
Improved survival in thromboti ...... al experience in 108 patients.
@en
type
label
Improved survival in thromboti ...... al experience in 108 patients.
@ast
Improved survival in thromboti ...... al experience in 108 patients.
@en
prefLabel
Improved survival in thromboti ...... al experience in 108 patients.
@ast
Improved survival in thromboti ...... al experience in 108 patients.
@en
P2093
P1476
Improved survival in thromboti ...... al experience in 108 patients.
@en
P2093
P304
P356
10.1056/NEJM199108083250605
P407
P577
1991-08-01T00:00:00Z